Kai Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kai Yuan has a total of 289 co-authors. Here are the top co-authors by number of shared publications:
Fang Chen
Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology, Xiangya Hospital & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China
22 shared publicationsLu Lv
Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology, Xiangya Hospital & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China
16 shared publicationsSong Mao
Institute of Molecular Precision Medicine, Xiangya Hospital, Central South University
16 shared publicationsZhuohua Zhang
Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology, Xiangya Hospital & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China
12 shared publicationsNa Zhang
Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology & Department of Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, China
11 shared publicationsChunhong Yu
Hunan Key Laboratory of Molecular Precision Medicine, Department of Oncology & Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China
9 shared publications
Latest Publications
- Open Access
NeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis
Tumor neoantigens derived from diverse molecular aberrations are important targets for personalized cancer immunotherapy, but existing resources incompletely integrate mass-spectrometry-supported canonical and non-canonical antigen evidence across cancer types. NeoOmni Atlas is an interactive pan-cancer T-cell epitope resource, built via proteogenomic reanalysis of 7,561 immunopeptidomics datasets comprising 511 million raw spectra from 2,341 samples across 26 cancer types. The analysis yielded 872,414 eluted canonical peptides and 198,961 non-canonical peptides spanning 18 molecular alteration classes, along with 759,386 unique ligands presented by 322 human leukocyte antigen (HLA) alleles. Relative to existing repositories, NeoOmni Atlas covers a broader range of cancer types, includes 60 additional HLA alleles, and catalogs 369,781 novel ligands. A computational tumor-specific filtering framework identified 316,126 tumor-associated epitopes and 61,231 tumor-specific epitopes. Tumor-specific epitopes showed stronger predicted binding affinity than tumor-associated epitopes for HLA class I A and B alleles, and 65 conserved tumor-specific epitopes recurrent across more than 10 tumor types represent potential shared antigen candidates. NeoOmni Atlas also prioritizes candidate tumor-associated antigens including PMEL (gp100:209–217) and CSPG4 , and supports browsing, searching, and downloading by cancer type, human leukocyte antigen allele, peptide sequence, and source event. NeoOmni Atlas is freely accessible at http://modinfor.com/NeoOmni-Atlas/ .
Open AccessNeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis
Tumor neoantigens derived from diverse molecular aberrations are important targets for personalized cancer immunotherapy, but existing resources incompletely integrate mass-spectrometry-supported canonical and non-canonical antigen evidence across cancer types. NeoOmni Atlas is an interactive pan-cancer T-cell epitope resource, built via proteogenomic reanalysis of 7,561 immunopeptidomics datasets comprising 511 million raw spectra from 2,341 samples across 26 cancer types. The analysis yielded 872,414 eluted canonical peptides and 198,961 non-canonical peptides spanning 18 molecular alteration classes, along with 759,386 unique ligands presented by 322 human leukocyte antigen (HLA) alleles. Relative to existing repositories, NeoOmni Atlas covers a broader range of cancer types, includes 60 additional HLA alleles, and catalogs 369,781 novel ligands. A computational tumor-specific filtering framework identified 316,126 tumor-associated epitopes and 61,231 tumor-specific epitopes. Tumor-specific epitopes showed stronger predicted binding affinity than tumor-associated epitopes for HLA class I A and B alleles, and 65 conserved tumor-specific epitopes recurrent across more than 10 tumor types represent potential shared antigen candidates. NeoOmni Atlas also prioritizes candidate tumor-associated antigens including PMEL (gp100:209–217) and CSPG4 , and supports browsing, searching, and downloading by cancer type, human leukocyte antigen allele, peptide sequence, and source event. NeoOmni Atlas is freely accessible at http://modinfor.com/NeoOmni-Atlas/ .
- Open Access
- 7 July 2026
- Published by Springer Nature in Research Square
ZNF582 inactivation unleashes HERVH-driven NF-kB signaling in cervical cancer
Persistent high-risk HPV infection initiates cervical cancer, but the host-cell programs that convert reversible epithelial lesions into invasive disease remain unclear. Here we identify HERVH as an endogenous retroviral amplifier of NF-κB signaling in cervical cancer. Pan-cancer analyses identified ZNF582, a cervical cancer triage marker, as a candidate repressor of HERVH. During cervical cancer progression, ZNF582 downregulation coincided with early and persistent HERVH activation. ZNF582 recognized HERVH DNA sequences and directed their epigenetic silencing, whereas ZNF582 loss unleashed HERVH transcription and promoted cervical cancer cell proliferation. Mechanistically, HERVH transcripts sequestered NF-κB repressing factor (NKRF), releasing a nuclear brake on NF-κB target-gene transcription. NF-κB inhibition suppressed HERVH-driven cervical cancer progression in mouse models and patient-derived organoids. These findings reveal a ZNF582–HERVH–NKRF–NF-κB axis that connects endogenous retroviral derepression to inflammatory tumor progression and nominates local NF-κB blockade as a potential interception strategy for epigenetically defined cervical disease.
- 7 July 2026
- Published by Springer Nature in Research Square
Open AccessZNF582 inactivation unleashes HERVH-driven NF-kB signaling in cervical cancer
Persistent high-risk HPV infection initiates cervical cancer, but the host-cell programs that convert reversible epithelial lesions into invasive disease remain unclear. Here we identify HERVH as an endogenous retroviral amplifier of NF-κB signaling in cervical cancer. Pan-cancer analyses identified ZNF582, a cervical cancer triage marker, as a candidate repressor of HERVH. During cervical cancer progression, ZNF582 downregulation coincided with early and persistent HERVH activation. ZNF582 recognized HERVH DNA sequences and directed their epigenetic silencing, whereas ZNF582 loss unleashed HERVH transcription and promoted cervical cancer cell proliferation. Mechanistically, HERVH transcripts sequestered NF-κB repressing factor (NKRF), releasing a nuclear brake on NF-κB target-gene transcription. NF-κB inhibition suppressed HERVH-driven cervical cancer progression in mouse models and patient-derived organoids. These findings reveal a ZNF582–HERVH–NKRF–NF-κB axis that connects endogenous retroviral derepression to inflammatory tumor progression and nominates local NF-κB blockade as a potential interception strategy for epigenetically defined cervical disease.
- Open Access
Asymmetric partition of the O -GlcNAcome in mitosis ensures binary cell fate decision
Many cellular components undergo biased segregation during stem cell division, but whether such order extends to the proteome has remained unknown. Using our real-time O -GlycoTracer, we find that O -GlcNAcylated proteins (the O -GlcNAcome) segregate asymmetrically during Drosophila neuroblast mitosis, predisposing the two daughters to distinct fates. The daughter that preserves stem cell identity inherits most of the O -GlcNAcome. This asymmetric partition requires putative O -GlcNAc readers, notably 14-3-3 proteins. We further identify the nuclear pore complex (NPC) as a major O -GlcNAc substrate in neuroblasts; Nup153, located in the nuclear basket, shows O -GlcNAc-dependent biased inheritance. Perturbing multiple steps in this segregation pathway disrupts neuroblast differentiation, reduces brain size, and causes adult learning deficits. These findings reveal a coordinated O -GlcNAc-driven mechanism for proteome-level asymmetric inheritance during neural stem cell division, with implications for neurodevelopmental disorders linked to OGT or 14-3-3 mutations.
Open AccessAsymmetric partition of the O -GlcNAcome in mitosis ensures binary cell fate decision
Many cellular components undergo biased segregation during stem cell division, but whether such order extends to the proteome has remained unknown. Using our real-time O -GlycoTracer, we find that O -GlcNAcylated proteins (the O -GlcNAcome) segregate asymmetrically during Drosophila neuroblast mitosis, predisposing the two daughters to distinct fates. The daughter that preserves stem cell identity inherits most of the O -GlcNAcome. This asymmetric partition requires putative O -GlcNAc readers, notably 14-3-3 proteins. We further identify the nuclear pore complex (NPC) as a major O -GlcNAc substrate in neuroblasts; Nup153, located in the nuclear basket, shows O -GlcNAc-dependent biased inheritance. Perturbing multiple steps in this segregation pathway disrupts neuroblast differentiation, reduces brain size, and causes adult learning deficits. These findings reveal a coordinated O -GlcNAc-driven mechanism for proteome-level asymmetric inheritance during neural stem cell division, with implications for neurodevelopmental disorders linked to OGT or 14-3-3 mutations.
- Open Access
- 23 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (18)
Mechanistic insights into Cas13d enzymes from cryo-EM structures of CasRx and DjCas13d
CasRx and its engineered variants have emerged as powerful RNA-targeting tools, exhibiting high specificity, robust efficiency, and minimal trans-cleavage activity. Recently, DjCas13d was identified as a promising alternative, offering even lower trans-cleavage activity while retaining comparable cis-cleavage efficiency. Despite their broad utility in biotechnology and therapeutic development, the molecular mechanisms governing substrate recognition and activation in these functionally relevant Cas13d enzymes remain incompletely understood. Here, we present comparative structural and biochemical analyses of CasRx and DjCas13d. Using cryogenic electron microscopy, we determined structures of both enzymes in binary (protein–crRNA) and ternary (protein–crRNA–target RNA) states, and additionally solved the apo structure of DjCas13d. Biochemical assays revealed that both enzymes exhibit similar cis-cleavage activity, whereas DjCas13d shows substantially reduced trans-cleavage activity relative to CasRx. Structural comparisons uncovered key conformational changes linked to target RNA engagement and catalytic activation, providing mechanistic insight into their distinct cleavage behaviors. Furthermore, structure-guided mutagenesis yielded several CasRx variants that achieve a favorable balance between reduced trans-cleavage activity and preserved cis-cleavage efficiency, representing valuable starting points for further optimization. Together, these findings advance our mechanistic understanding of Cas13 enzymes and provide a structural framework for the rational design of RNA-targeting technologies.
- 23 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (18)
Open AccessMechanistic insights into Cas13d enzymes from cryo-EM structures of CasRx and DjCas13d
CasRx and its engineered variants have emerged as powerful RNA-targeting tools, exhibiting high specificity, robust efficiency, and minimal trans-cleavage activity. Recently, DjCas13d was identified as a promising alternative, offering even lower trans-cleavage activity while retaining comparable cis-cleavage efficiency. Despite their broad utility in biotechnology and therapeutic development, the molecular mechanisms governing substrate recognition and activation in these functionally relevant Cas13d enzymes remain incompletely understood. Here, we present comparative structural and biochemical analyses of CasRx and DjCas13d. Using cryogenic electron microscopy, we determined structures of both enzymes in binary (protein–crRNA) and ternary (protein–crRNA–target RNA) states, and additionally solved the apo structure of DjCas13d. Biochemical assays revealed that both enzymes exhibit similar cis-cleavage activity, whereas DjCas13d shows substantially reduced trans-cleavage activity relative to CasRx. Structural comparisons uncovered key conformational changes linked to target RNA engagement and catalytic activation, providing mechanistic insight into their distinct cleavage behaviors. Furthermore, structure-guided mutagenesis yielded several CasRx variants that achieve a favorable balance between reduced trans-cleavage activity and preserved cis-cleavage efficiency, representing valuable starting points for further optimization. Together, these findings advance our mechanistic understanding of Cas13 enzymes and provide a structural framework for the rational design of RNA-targeting technologies.
- Open Access
- 11 August 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (15)
Ints7 deficiency activates DNA damage response to elicit resurgence of endogenous retrovirus MERVL and anastasis of embryonic stem cells
The murine endogenous retrovirus MERVL is dynamically activated in a small population of in vitro cultured mouse embryonic stem cells (mESCs) exhibiting totipotent-like features. Yet, the relationship between MERVL activation and cell fate decisions of mESCs is incompletely understood. Through a genome-wide knockout screen, we discovered that MERVL activity is intrinsically linked to DNA damage response pathways. Loss of Ints7, a backbone subunit of the Integrator complex, increased DNA damage and triggered MERVL expression. Mechanistically, Ints7 depletion induced phosphorylation of Kap1, increased chromatin accessibility at MERVL loci, and activated the p53–Dux axis to drive MERVL transcription. Intriguingly, DNA damage-induced MERVL resurgence followed the cleavage of caspase-3, often accompanying a process known as anastasis—cell survival after transient apoptotic signaling. Collectively, our study uncovered that MERVL activation in mESCs is integrated into the cellular circuit for decision-making in response to DNA damage, suggesting that sublethal caspase activation can influence the developmental potential of stem cells.
- 11 August 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (15)
Open AccessInts7 deficiency activates DNA damage response to elicit resurgence of endogenous retrovirus MERVL and anastasis of embryonic stem cells
The murine endogenous retrovirus MERVL is dynamically activated in a small population of in vitro cultured mouse embryonic stem cells (mESCs) exhibiting totipotent-like features. Yet, the relationship between MERVL activation and cell fate decisions of mESCs is incompletely understood. Through a genome-wide knockout screen, we discovered that MERVL activity is intrinsically linked to DNA damage response pathways. Loss of Ints7, a backbone subunit of the Integrator complex, increased DNA damage and triggered MERVL expression. Mechanistically, Ints7 depletion induced phosphorylation of Kap1, increased chromatin accessibility at MERVL loci, and activated the p53–Dux axis to drive MERVL transcription. Intriguingly, DNA damage-induced MERVL resurgence followed the cleavage of caspase-3, often accompanying a process known as anastasis—cell survival after transient apoptotic signaling. Collectively, our study uncovered that MERVL activation in mESCs is integrated into the cellular circuit for decision-making in response to DNA damage, suggesting that sublethal caspase activation can influence the developmental potential of stem cells.
- 3 July 2025
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 228, 110202
Photoreceptor-dependent signaling in plant responses to thermomorphogenesis and heat stress
- 3 July 2025
- Published by Elsevier in Plant Physiology and Biochemistry
- Vol. 228, 110202
Photoreceptor-dependent signaling in plant responses to thermomorphogenesis and heat stress
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (4)
Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas
A fundamental principle of immunotherapy is that T cells are capable of detecting tumor epitopes presented on cancer cell surfaces. Immunopeptidomic strategies empowered by liquid chromatography–tandem mass spectrometry have transformed tumor epitopes identification and provided novel insights into tumor immunology. It enables in-depth profiling of major histocompatibility complex (MHC) presented ligands, thereby offering valuable perspectives on the molecular dialog among tumor and T cells. Here, we developed an immune-ligand identification and analysis pipeline from large-scale immunopeptidomics data. Through an extensive collection and processing of 5821 immunopeptidomic samples, which amounted to 305.7 million MS2 spectra, we identified 24 380 595 peptide-spectrum matches from these samples and further detected a total of 1 017 731 unique MHC immune ligands. These ligands were deconvolved and classified to specific HLA alleles. In total, we detected 582 852 HLA-I peptides and 434 879 HLA-II peptides that can bind to 292 HLA alleles, thereby greatly expanding the cancer immunopeptidome. Additionally, we identified and annotated 372 720 tumor-associated post-translational modification (PTM) peptides, revealing the comprehensive landscape of PTM antigens. All ligands and annotations were aggregated into Ligand.MHC Atlas, a comprehensive repository dedicated to tumor-derived HLA-presented ligands across 26 major human cancers (54 subtypes). Overall, our study uniquely integrates batch-effect correction, leverages the optimized software with novel deconvolution approach for immunopeptidomics analysis and ligand identification, and provides a public web portal with a comprehensive HLA ligand repository. Ligand.MHC Atlas functions as an invaluable resource, offering crucial understandings into immunology investigations. It will accelerate the advancement of cancer vaccines and immunotherapies. Ligand.MHC Atlas is available at http://modinfor.com/Ligand.MHC-Atlas/.
- 2 July 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (4)
Open AccessDeciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas
A fundamental principle of immunotherapy is that T cells are capable of detecting tumor epitopes presented on cancer cell surfaces. Immunopeptidomic strategies empowered by liquid chromatography–tandem mass spectrometry have transformed tumor epitopes identification and provided novel insights into tumor immunology. It enables in-depth profiling of major histocompatibility complex (MHC) presented ligands, thereby offering valuable perspectives on the molecular dialog among tumor and T cells. Here, we developed an immune-ligand identification and analysis pipeline from large-scale immunopeptidomics data. Through an extensive collection and processing of 5821 immunopeptidomic samples, which amounted to 305.7 million MS2 spectra, we identified 24 380 595 peptide-spectrum matches from these samples and further detected a total of 1 017 731 unique MHC immune ligands. These ligands were deconvolved and classified to specific HLA alleles. In total, we detected 582 852 HLA-I peptides and 434 879 HLA-II peptides that can bind to 292 HLA alleles, thereby greatly expanding the cancer immunopeptidome. Additionally, we identified and annotated 372 720 tumor-associated post-translational modification (PTM) peptides, revealing the comprehensive landscape of PTM antigens. All ligands and annotations were aggregated into Ligand.MHC Atlas, a comprehensive repository dedicated to tumor-derived HLA-presented ligands across 26 major human cancers (54 subtypes). Overall, our study uniquely integrates batch-effect correction, leverages the optimized software with novel deconvolution approach for immunopeptidomics analysis and ligand identification, and provides a public web portal with a comprehensive HLA ligand repository. Ligand.MHC Atlas functions as an invaluable resource, offering crucial understandings into immunology investigations. It will accelerate the advancement of cancer vaccines and immunotherapies. Ligand.MHC Atlas is available at http://modinfor.com/Ligand.MHC-Atlas/.
- 16 May 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (7) , 1193-1204
DEK–nucleosome structure shows DEK modulates H3K27me3 and stem cell fate
DEK is a highly conserved chromatin-associated oncoprotein that has important roles in regulating chromatin dynamics and stem cell fate. Dysregulation of DEK is associated with stem cell dysfunction and cancers, including acute myeloid leukemia. Despite its importance in chromatin regulation, the structural mechanisms underlying DEK’s interaction with chromatin and its influence on gene regulation remain poorly understood. Here we combined cryogenic electron microscopy (cryo-EM), biochemical and cellular approaches to investigate the molecular mechanisms and functional importance of DEK’s interaction with chromatin. Our cryo-EM structures reveal the structural basis of the DEK–nucleosome interaction. Biochemical and cellular results demonstrate that this interaction is crucial for DEK deposition onto chromatin. Furthermore, our results reveal that DEK safeguards mouse embryonic stem cells from acquiring primitive endoderm fates by modulating the repressive histone mark H3K27me3. Together, our study provides crucial molecular insights into the structure and function of DEK, establishing a framework for understanding its roles in chromatin biology and cell fate determination.
- 16 May 2025
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 32 (7) , 1193-1204
DEK–nucleosome structure shows DEK modulates H3K27me3 and stem cell fate
DEK is a highly conserved chromatin-associated oncoprotein that has important roles in regulating chromatin dynamics and stem cell fate. Dysregulation of DEK is associated with stem cell dysfunction and cancers, including acute myeloid leukemia. Despite its importance in chromatin regulation, the structural mechanisms underlying DEK’s interaction with chromatin and its influence on gene regulation remain poorly understood. Here we combined cryogenic electron microscopy (cryo-EM), biochemical and cellular approaches to investigate the molecular mechanisms and functional importance of DEK’s interaction with chromatin. Our cryo-EM structures reveal the structural basis of the DEK–nucleosome interaction. Biochemical and cellular results demonstrate that this interaction is crucial for DEK deposition onto chromatin. Furthermore, our results reveal that DEK safeguards mouse embryonic stem cells from acquiring primitive endoderm fates by modulating the repressive histone mark H3K27me3. Together, our study provides crucial molecular insights into the structure and function of DEK, establishing a framework for understanding its roles in chromatin biology and cell fate determination.
- Open Access
- 2 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy
Protein O-GlcNAcylation is a post-translational modification coupled to cellular metabolic plasticity. Aberrant O-GlcNAcylation has been observed in many cancers including endometrial cancer (EC), a common malignancy in women. However, clinical characterization of dysregulated O-GlcNAcylation homeostasis in EC and interrogating its molecular mechanism remain incomplete. Here we report that O-GlcNAcylation level is positively correlated with EC histologic grade in a Chinese cohort containing 219 tumors, validated in The Cancer Genome Atlas dataset. Increasing O-GlcNAcylation in patient-derived endometrial epithelial organoids promotes proliferation and stem-like cell properties, whereas decreasing O-GlcNAcylation limits the growth of endometrial cancer organoids. CRISPR screen and biochemical characterization reveal that tumor suppressor F-box only protein 31 (FBXO31) regulates O-GlcNAcylation homeostasis in EC by ubiquitinating the O-GlcNAc transferase OGT. Downregulation of O-GlcNAcylation impedes EC tumor formation in mouse models. Collectively, our study highlights O-GlcNAcylation as a useful stratification marker and a therapeutic vulnerability for the advanced, poorly differentiated EC cases.
- 2 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-22
Open AccessFBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy
Protein O-GlcNAcylation is a post-translational modification coupled to cellular metabolic plasticity. Aberrant O-GlcNAcylation has been observed in many cancers including endometrial cancer (EC), a common malignancy in women. However, clinical characterization of dysregulated O-GlcNAcylation homeostasis in EC and interrogating its molecular mechanism remain incomplete. Here we report that O-GlcNAcylation level is positively correlated with EC histologic grade in a Chinese cohort containing 219 tumors, validated in The Cancer Genome Atlas dataset. Increasing O-GlcNAcylation in patient-derived endometrial epithelial organoids promotes proliferation and stem-like cell properties, whereas decreasing O-GlcNAcylation limits the growth of endometrial cancer organoids. CRISPR screen and biochemical characterization reveal that tumor suppressor F-box only protein 31 (FBXO31) regulates O-GlcNAcylation homeostasis in EC by ubiquitinating the O-GlcNAc transferase OGT. Downregulation of O-GlcNAcylation impedes EC tumor formation in mouse models. Collectively, our study highlights O-GlcNAcylation as a useful stratification marker and a therapeutic vulnerability for the advanced, poorly differentiated EC cases.
- Open Access
- 1 January 2025
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 15 (1366) , e5234
Tissue-Specific Profiling of O-GlcNAcylated Proteins in Drosophila Using TurboID-CpOGAM
Protein O-GlcNAcylation is a prevalent and dynamic post-translational modification that targets a multitude of nuclear and cytoplasmic proteins. Through the modification of diverse substrates, O-GlcNAcylation plays a pivotal role in essential cellular processes, including transcription, translation, and protein homeostasis. Dysregulation of O-GlcNAc homeostasis has been implicated in a variety of diseases, including cardiovascular diseases, cancer, and neurodegenerative diseases. Studying O-GlcNAcylated proteins in different tissues is crucial to understanding the pathogenesis of these diseases. However, identifying phenotype-relevant candidate substrates in a tissue-specific manner remains unfeasible. We developed a novel tool for the analysis of O-GlcNAcylated proteins, combining a catalytically inactive CpOGA mutant CpOGACD and TurboID proximity labeling technology. This tool converts O-GlcNAc modifications into biotin labeling, enabling the enrichment and mass spectrometry (MS) identification of O-GlcNAcylated proteins in specific tissues. Meanwhile, TurboID-CpOGADM, which carries two point mutations that inactivate both its catalytic and binding activities toward O-GlcNAc modification, was used as a control to differentiate O-GlcNAc-independent protein–protein interactions. We have successfully used TurboID-CpOGACD/DM (TurboID-CpOGAM) to enrich O-GlcNAc proteins in Drosophila combining the UAS/Gal4 system. Our protocol provides a comprehensive workflow for tissue-specific enrichment of candidate O-GlcNAcylated substrates and offers a valuable tool for dissecting tissue-specific O-GlcNAcylation functions in Drosophila.
- 1 January 2025
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 15 (1366) , e5234
Open AccessTissue-Specific Profiling of O-GlcNAcylated Proteins in Drosophila Using TurboID-CpOGAM
Protein O-GlcNAcylation is a prevalent and dynamic post-translational modification that targets a multitude of nuclear and cytoplasmic proteins. Through the modification of diverse substrates, O-GlcNAcylation plays a pivotal role in essential cellular processes, including transcription, translation, and protein homeostasis. Dysregulation of O-GlcNAc homeostasis has been implicated in a variety of diseases, including cardiovascular diseases, cancer, and neurodegenerative diseases. Studying O-GlcNAcylated proteins in different tissues is crucial to understanding the pathogenesis of these diseases. However, identifying phenotype-relevant candidate substrates in a tissue-specific manner remains unfeasible. We developed a novel tool for the analysis of O-GlcNAcylated proteins, combining a catalytically inactive CpOGA mutant CpOGACD and TurboID proximity labeling technology. This tool converts O-GlcNAc modifications into biotin labeling, enabling the enrichment and mass spectrometry (MS) identification of O-GlcNAcylated proteins in specific tissues. Meanwhile, TurboID-CpOGADM, which carries two point mutations that inactivate both its catalytic and binding activities toward O-GlcNAc modification, was used as a control to differentiate O-GlcNAc-independent protein–protein interactions. We have successfully used TurboID-CpOGACD/DM (TurboID-CpOGAM) to enrich O-GlcNAc proteins in Drosophila combining the UAS/Gal4 system. Our protocol provides a comprehensive workflow for tissue-specific enrichment of candidate O-GlcNAcylated substrates and offers a valuable tool for dissecting tissue-specific O-GlcNAcylation functions in Drosophila.